🏷

Classifications

Harrison's Chapter

🔗

Mappings

MONDO

MONDO:0018931 mucolipidosis type III, alpha/beta

Orphanet ORPHA:423461 lists MONDO:0018931 as an exact cross-reference for mucolipidosis type III alpha/beta.

📘

Definitions

1

Orphanet mucolipidosis type III alpha/beta definition

A lysosomal disorder characterized by early-childhood growth slowing, joint stiffness and pain, gradual facial coarsening, moderate developmental delay, and mild intellectual disability in most patients.

OTHER

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"Mucolipidosis III alpha/beta (MLIII alpha/beta) is a lysosomal disorder characterized by progressive slowing of the growth rate from early childhood, stiffness and pain in joints, gradual coarsening of facial features, moderate developmental delay and mild intellectual disability in most patients."

Orphanet defines the disorder and its core clinical manifestations.

👪

Inheritance

1

Autosomal recessive inheritance HP:0000007

Mucolipidosis type III alpha/beta is inherited in an autosomal recessive pattern.

Autosomal recessive inheritance

Show evidence (2 references)

ORPHA:423461 SUPPORT Other

"Autosomal recessive"

Orphanet records autosomal recessive inheritance.

PMID:20301730 SUPPORT Human Clinical

"ML III alpha/beta is inherited in an autosomal recessive manner."

GeneReviews states autosomal recessive inheritance for ML III alpha/beta.

⚙

Pathophysiology

9

GNPTAB phosphotransferase deficiency

Biallelic pathogenic GNPTAB variants reduce activity of the alpha/beta subunits of UDP-N-acetylglucosamine-1-phosphotransferase, preventing normal synthesis of mannose-6-phosphate recognition markers on lysosomal hydrolases.

GNPTAB link

protein targeting to lysosome link ↓ DECREASED

lysosome link

Downstream

Lysosomal hydrolase mistargeting and secretion Loss of phosphotransferase activity impairs mannose-6-phosphate recognition-marker synthesis on lysosomal hydrolases.

GlcNAc-1-phosphotransferase activity GNPTAB alpha/beta subunit deficiency is measured as markedly decreased GlcNAc-1-phosphotransferase activity.

Show evidence (2 references)

DOI:10.1136/jmg.2009.067736 SUPPORT Human Clinical

"The disorders are caused by mutations in GNPTAB, which encodes two of three subunits of the heterohexameric enzyme, N-acetylglucosamine-1-phosphotransferase."

The cohort directly links ML II/III alpha/beta to GNPTAB mutations and the phosphotransferase enzyme.

PMID:19197337 SUPPORT Human Clinical

"diseases caused by a deficiency of alpha and/or beta subunits of the enzyme N-acetylglucosamine-1-phosphotransferase, which is encoded by the GNPTAB gene."

The Japanese cohort independently supports GNPTAB-encoded alpha/beta subunit deficiency.

Lysosomal hydrolase mistargeting and secretion

Hydrolases lacking mannose-6-phosphate tags fail to localize efficiently to lysosomes, producing elevated extracellular lysosomal enzyme activities and deficient intracellular lysosomal degradation.

protein localization to lysosome link ↓ DECREASED lysosomal transport link ↓ DECREASED

lysosomal lumen link

Downstream

Intracellular glycosphingolipid and glycosaminoglycan storage Failed lysosomal delivery of degradative enzymes leaves macromolecules incompletely degraded inside cells.

Diagnostic lysosomal hydrolase disparity The secretion/localization defect produces elevated plasma hydrolases and deficient intracellular enzyme activity.

Show evidence (2 references)

PMID:21466370 SUPPORT Human Clinical

"Without these important recognition markers, lysosomal enzymes are not transported to the lysosomes; instead, they leak out of cells, and the serum levels of these enzymes are higher than normal."

Autopsy review directly explains lysosomal hydrolase mistargeting and extracellular leakage.

PMID:20301730 SUPPORT Human Clinical

"the activity of nearly all lysosomal hydrolases is up to tenfold higher in plasma and other body fluids than in normal controls because of inadequate targeting to lysosomes."

GeneReviews supports elevated plasma and fluid hydrolases due to inadequate lysosomal targeting.

Intracellular glycosphingolipid and glycosaminoglycan storage

Incompletely degraded glycosaminoglycans, sphingolipids, and related macromolecules accumulate in lysosomes across connective tissue, cardiac, neural, cartilage, and fibroblast-rich tissues.

fibroblast link chondrocyte link

glycosaminoglycan catabolic process link ↓ DECREASED glycosphingolipid catabolic process link ↓ DECREASED

lysosome link

Downstream

Skeletal and joint degeneration Connective-tissue and skeletal storage contributes to the dominant skeletal and joint phenotype.

Cardiac valve and myocardial involvement Cardiac and valvular tissues can accumulate storage material, contributing to valve and myocardial disease.

Somatic growth impairment Residual ML III storage disease impairs childhood growth, producing postnatal growth slowing and short stature.

Craniofacial and connective tissue involvement Storage in fibroblast-rich connective tissues contributes to facial, gingival, skin, abdominal wall, and ocular surface manifestations.

Airway, middle ear, and hearing involvement Cartilage, airway, middle-ear, and respiratory involvement connects lysosomal storage to recurrent otitis, hearing impairment, hoarse voice, and recurrent respiratory infections.

Mild CNS storage and cognitive involvement Mild lysosomal storage in neurons and glia provides a mechanistic branch for developmental delay and cognitive impairment.

Oligosacchariduria Impaired lysosomal glycan degradation produces excessive urinary oligosaccharide excretion.

Keratan sulfate excretion in urine Glycosaminoglycan storage and turnover can present as urinary keratan sulfate excretion.

Show evidence (2 references)

PMID:20367762 SUPPORT Human Clinical

"global deficiencies of lysosomal degradative enzymes with concomitant intracellular accumulation of both partly degraded glycosaminoglycans and sphingolipids."

The natural-history study links defective hydrolase targeting to intracellular storage products.

PMID:21466370 SUPPORT Human Clinical

"Accumulation of mucopolysaccharides along with lipids within lysosomes of patients with mucolipidosis is the characteristic abnormality."

Autopsy review identifies lysosomal mucopolysaccharide and lipid storage as characteristic.

Skeletal and joint degeneration

ML III skeletal disease combines dysostosis multiplex, osteodystrophy, progressive osteoarthritis, cartilage destruction, bone lesions, bone pain, joint stiffness, and entrapment neuropathy.

chondrocyte link osteoclast link

Downstream

Joint stiffness Joint stiffness is a very frequent skeletal/joint manifestation.

Bone pain Bone pain is a frequent clinical consequence of skeletal disease.

Dysostosis multiplex Dysostosis multiplex is part of the radiographic skeletal phenotype.

Generalized osteoporosis Osteopenia and osteoporosis are part of the osteodystrophy.

Kyphoscoliosis Spinal skeletal involvement includes thoracolumbar kyphosis and scoliosis.

Osteolysis Progressive osteodystrophy includes severe carpal and femoral osteolysis.

Constrictive median neuropathy Carpal tunnel syndrome is common in adults with ML III.

Loss of ambulation Progressive skeletal and joint disease can impair mobility and produce wheelchair dependence.

Flexion contracture Joint disease causes hip, knee, and other flexion contractures that require physiotherapy.

Gait disturbance Progressive skeletal and joint disease disturbs gait and mobility.

Short neck Skeletal and connective tissue involvement includes short neck morphology.

Show evidence (2 references)

PMID:29704188 SUPPORT Human Clinical

"All patients had dysostosis multiplex and progressive secondary osteoarthritis, characterised by cartilage destruction and bone lesions in multiple joints."

Adult cohort supports progressive skeletal and joint degeneration in ML III.

PMID:12705498 SUPPORT Human Clinical

"Biochemical indices of bone turnover were increased, and transiliac bone biopsy demonstrated both trabecular osteopenia and marked subperiosteal bone resorption."

The pamidronate study supports osteodystrophy with high bone turnover and osteopenia.

Cardiac valve and myocardial involvement

Lysosomal storage in cardiovascular tissues produces valve thickening and insufficiency, most often involving mitral and aortic valves, and can rarely involve myocardium or right ventricular function.

cardiac muscle cell link

heart link

Downstream

Mitral regurgitation Mitral valve insufficiency is a frequent cardiac manifestation.

Aortic regurgitation Aortic valve insufficiency is a frequent cardiac manifestation.

Congestive heart failure Progressive cardiorespiratory disease can culminate in heart failure.

Right ventricular hypertrophy Right ventricular structural involvement is an occasional cardiac feature.

Show evidence (2 references)

PMID:32818557 SUPPORT Human Clinical

"The most documented cardiac manifestation is the thickening and insufficiency of mitral and aortic valves, but there are very few reports about the myocardial involvement."

Cardiology case report supports valve insufficiency and rare myocardial involvement in ML III alpha/beta.

PMID:21466370 SUPPORT Human Clinical

"Valvular cardiac disease has also been well established in ML III."

Autopsy review supports established valvular cardiac disease.

Somatic growth impairment

Childhood-onset ML III alpha/beta causes slowing of growth after early childhood and produces persistent short stature.

Downstream

Short stature Persistent postnatal growth slowing produces short stature.

Postnatal growth retardation Growth slowing after early childhood is captured clinically as postnatal growth retardation.

Show evidence (2 references)

PMID:20301730 SUPPORT Human Clinical

"a slowly progressive disorder with clinical onset at approximately age three years, is characterized by slow growth rate and subnormal stature"

GeneReviews supports slow growth rate and subnormal stature in ML III alpha/beta.

DOI:10.1136/jmg.2009.067736 SUPPORT Human Clinical

"ML III retains a low level of phosphotransferase activity because of at least one missense or splice site mutation. The phenotype is milder, with minimal delays in milestones, the appearance of facial coarsening by early school age, and slowing of growth after the age of 4 years."

Large cohort supports growth slowing in the attenuated ML III phenotype.

Craniofacial and connective tissue involvement

Lysosomal storage in fibroblast-rich connective tissues and related Hurler-like tissue involvement produces facial coarsening, gingival overgrowth, thickened skin, abdominal wall findings, and ocular surface manifestations.

fibroblast link

Downstream

Gingival overgrowth Connective-tissue storage can produce gingival enlargement.

Coarse facial features Facial connective-tissue involvement produces gradual facial coarsening.

Epicanthus Craniofacial involvement includes epicanthal folds.

Full cheeks Craniofacial involvement includes full cheeks.

Thickened skin Skin fibroblast storage is consistent with thickened skin.

Umbilical hernia Connective-tissue and abdominal-wall involvement can produce umbilical hernia.

Diastasis recti Abdominal-wall connective-tissue involvement can produce diastasis recti.

Abdominal wall muscle weakness Abdominal-wall involvement can manifest as abdominal wall muscle weakness.

Depressed nasal bridge Craniofacial involvement includes depressed nasal bridge.

Proptosis Craniofacial and orbital connective-tissue involvement can present as proptosis.

Corneal opacity Ocular connective-tissue involvement can produce mild corneal clouding or opacity.

Show evidence (2 references)

PMID:21466370 SUPPORT Human Clinical

"The external exam revealed a patient of short stature (138 cm) weighing 43 kg with slightly coarsened facial features. She appeared younger than her stated age with pale white to waxy skin."

Autopsy examination supports facial and skin involvement in ML III.

ORPHA:423461 SUPPORT Other

"Mucolipidosis III alpha/beta (MLIII alpha/beta) is a lysosomal disorder characterized by progressive slowing of the growth rate from early childhood, stiffness and pain in joints, gradual coarsening of facial features, moderate developmental delay and mild intellectual disability in most patients."

Orphanet definition supports gradual facial coarsening as a core manifestation.

Airway, middle ear, and hearing involvement

ML III alpha/beta affects airway cartilage and recurrent middle-ear disease, producing otitis media, hearing impairment, hoarse voice, and recurrent respiratory infections.

chondrocyte link

Downstream

Recurrent otitis media Middle-ear involvement causes recurrent otitis media.

Conductive hearing impairment Recurrent middle-ear disease can cause conductive hearing impairment.

Sensorineural hearing impairment Less commonly, hearing involvement includes sensorineural hearing impairment.

Hoarse voice Airway and laryngeal involvement can present with hoarse voice.

Recurrent upper respiratory tract infections Airway involvement predisposes to recurrent respiratory infections.

Show evidence (2 references)

PMID:20367762 SUPPORT Human Clinical

"Chronic otitis media was present in 7/10 patients."

Natural-history cohort supports frequent middle-ear involvement.

PMID:21466370 SUPPORT Human Clinical

"The lungs revealed patchy fibrosis and prominent chronic inflammation with increased intra-alveolar macrophages and lymphocytes as well as evidence of resolving aspiration pneumonia."

Autopsy supports clinically important respiratory involvement.

Mild CNS storage and cognitive involvement

Attenuated neuronal and glial lysosomal storage in ML III alpha/beta can accompany mild developmental or cognitive impairment.

neuron link glial cell link

Downstream

Cognitive impairment Mild CNS storage and development effects can present as cognitive impairment.

Show evidence (2 references)

PMID:21466370 SUPPORT Human Clinical

"By electron microscopy there were scattered, diffuse vesicular cytoplasmic granules in neurons and glia and an increase in lysosomal structures with fine electron lucent granularity in the above tissue types."

Autopsy documents neuronal and glial lysosomal storage in ML III alpha/beta.

PMID:20301730 SUPPORT Human Clinical

"gradual mild coarsening of facial features; and normal to mildly impaired cognitive development."

GeneReviews supports mild cognitive involvement in some patients.

✶

Histopathology

2

Lysosomal granular storage inclusions

Autopsy and ultrastructural examination show increased lysosomal granules in brain, heart, mitral valve, cartilage, skin, and liver fibroblasts, consistent with multisystem lysosomal storage.

Show evidence (2 references)

PMID:21466370 SUPPORT Human Clinical

"Overall, the electron microscopic exam was significant for an increased number of intracellular lysosomal granules, particularly in the brain but also in cells of the heart, mitral valve, cartilage, and fibroblasts within the skin and liver."

Autopsy directly documents multisystem intracellular lysosomal granules.

PMID:21466370 SUPPORT Human Clinical

"Cartilage of the trachea was notable for disordered collagen deposition and increased cellularity. Some of the chondrocytes were enlarged with granular, vacuolated cytoplasm."

Autopsy supports cartilage and chondrocyte storage pathology.

Bone osteodystrophy

Bone histology and imaging show osteopenia, osteoclastic subperiosteal bone resorption, marrow fibrosis, increased osteoid, and other features of a metabolic bone disorder.

Show evidence (2 references)

PMID:12705498 SUPPORT Human Clinical

"transiliac bone biopsy demonstrated both trabecular osteopenia and marked subperiosteal bone resorption."

Bone biopsy supports osteodystrophy and osteopenic/resorptive pathology.

PMID:21466370 SUPPORT Human Clinical

"Bone histopathology has been characterized by vigorous osteoclastic subperiosteal bone resorption, endosteal modeling, slight marrow fibrosis, and an increase in the amount of osteoid present."

Autopsy review supports characteristic bone histopathologic changes.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

36

Cardiovascular 2

Congestive heart failure OCCASIONAL Congestive heart failure (HP:0001635)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0001635 | Congestive heart failure | Occasional (29-5%)"

Orphanet provides the phenotype association and frequency band.

Aortic regurgitation FREQUENT Aortic regurgitation (HP:0001659)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0001659 | Aortic regurgitation | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Ear 3

Recurrent otitis media FREQUENT Recurrent otitis media (HP:0000403)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0000403 | Recurrent otitis media | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Conductive hearing impairment FREQUENT Conductive hearing impairment (HP:0000405)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0000405 | Conductive hearing impairment | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Sensorineural hearing impairment VERY_RARE Sensorineural hearing impairment (HP:0000407)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0000407 | Sensorineural hearing impairment | Very rare (<4-1%)"

Orphanet provides the phenotype association and frequency band.

Eye 2

Proptosis VERY_RARE Proptosis (HP:0000520)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0000520 | Proptosis | Very rare (<4-1%)"

Orphanet provides the phenotype association and frequency band.

Corneal opacity OCCASIONAL Corneal opacity (HP:0007957)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0007957 | Corneal opacity | Occasional (29-5%)"

Orphanet provides the phenotype association and frequency band.

Head and Neck 4

Coarse facial features FREQUENT Coarse facial features (HP:0000280)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0000280 | Coarse facial features | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Epicanthus FREQUENT Epicanthus (HP:0000286)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0000286 | Epicanthus | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Short neck FREQUENT Short neck (HP:0000470)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0000470 | Short neck | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Depressed nasal bridge FREQUENT Depressed nasal bridge (HP:0005280)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0005280 | Depressed nasal bridge | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Integument 1

Thickened skin FREQUENT Thickened skin (HP:0001072)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0001072 | Thickened skin | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Musculoskeletal 5

Dysostosis multiplex FREQUENT Dysostosis multiplex (HP:0000943)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0000943 | Dysostosis multiplex | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Flexion contracture FREQUENT Flexion contracture (HP:0001371)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0001371 | Flexion contracture | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Joint stiffness VERY_FREQUENT Joint stiffness (HP:0001387)

Show evidence (2 references)

ORPHA:423461 SUPPORT Other

"HP:0001387 | Joint stiffness | Very frequent (99-80%)"

Orphanet provides the phenotype association and frequency band.

PMID:10472261 SUPPORT Human Clinical

"Their main symptoms were carpal tunnel syndrome, trigger fingers and generalized joint stiffness."

Orthopedic case series independently supports generalized joint stiffness.

Kyphoscoliosis FREQUENT Kyphoscoliosis (HP:0002751)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0002751 | Kyphoscoliosis | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Osteolysis OCCASIONAL Osteolysis (HP:0002797)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0002797 | Osteolysis | Occasional (29-5%)"

Orphanet provides the phenotype association and frequency band.

Nervous System 2

Gait disturbance FREQUENT Gait disturbance (HP:0001288)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0001288 | Gait disturbance | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Cognitive impairment OCCASIONAL Cognitive impairment (HP:0100543)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0100543 | Cognitive impairment | Occasional (29-5%)"

Orphanet provides the phenotype association and frequency band.

Voice 1

Hoarse voice OCCASIONAL Hoarse voice (HP:0001609)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0001609 | Hoarse voice | Occasional (29-5%)"

Orphanet provides the phenotype association and frequency band.

Constitutional 1

Bone pain FREQUENT Bone pain (HP:0002653)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0002653 | Bone pain | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Growth 2

Short stature VERY_FREQUENT Short stature (HP:0004322)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0004322 | Short stature | Very frequent (99-80%)"

Orphanet provides the phenotype association and frequency band.

Postnatal growth retardation VERY_FREQUENT Postnatal growth retardation (HP:0008897)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0008897 | Postnatal growth retardation | Very frequent (99-80%)"

Orphanet provides the phenotype association and frequency band.

Other 13

Gingival overgrowth FREQUENT Gingival overgrowth (HP:0000212)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0000212 | Gingival overgrowth | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Full cheeks FREQUENT Full cheeks (HP:0000293)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0000293 | Full cheeks | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Umbilical hernia OCCASIONAL Umbilical hernia (HP:0001537)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0001537 | Umbilical hernia | Occasional (29-5%)"

Orphanet provides the phenotype association and frequency band.

Diastasis recti OCCASIONAL Diastasis recti (HP:0001540)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0001540 | Diastasis recti | Occasional (29-5%)"

Orphanet provides the phenotype association and frequency band.

Mitral regurgitation FREQUENT Mitral regurgitation (HP:0001653)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0001653 | Mitral regurgitation | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Right ventricular hypertrophy OCCASIONAL Right ventricular hypertrophy (HP:0001667)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0001667 | Right ventricular hypertrophy | Occasional (29-5%)"

Orphanet provides the phenotype association and frequency band.

Loss of ambulation OCCASIONAL Loss of ambulation (HP:0002505)

Show evidence (2 references)

ORPHA:423461 SUPPORT Other

"HP:0002505 | Loss of ambulation | Occasional (29-5%)"

Orphanet provides the phenotype association and frequency band.

PMID:29704188 SUPPORT Human Clinical

"Six patients (46%) needed help with activities of daily living (ADL) or were wheelchair-dependent."

Adult cohort supports mobility loss or wheelchair dependence in a substantial subset.

Recurrent upper respiratory tract infections OCCASIONAL Recurrent upper respiratory tract infections (HP:0002788)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0002788 | Recurrent upper respiratory tract infections | Occasional (29-5%)"

Orphanet provides the phenotype association and frequency band.

Abdominal wall muscle weakness FREQUENT Abdominal wall muscle weakness (HP:0009023)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0009023 | Abdominal wall muscle weakness | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Oligosacchariduria VERY_FREQUENT Oligosacchariduria (HP:0010471)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0010471 | Oligosacchariduria | Very frequent (99-80%)"

Orphanet provides the phenotype association and frequency band.

Keratan sulfate excretion in urine FREQUENT Keratan sulfate excretion in urine (HP:0012069)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0012069 | Keratan sulfate excretion in urine | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

Constrictive median neuropathy OCCASIONAL Constrictive median neuropathy (HP:0012185)

Orphanet records constrictive median neuropathy as occasional across ML III alpha/beta, while the adult cohort in PMID:29704188 reported carpal tunnel syndrome in 92% of adult patients, consistent with higher frequency after long-standing skeletal and joint disease.

Show evidence (2 references)

ORPHA:423461 SUPPORT Other

"HP:0012185 | Constrictive median neuropathy | Occasional (29-5%)"

Orphanet provides the phenotype association and frequency band.

PMID:29704188 SUPPORT Human Clinical

"Carpal tunnel syndrome (CTS) was found in 12 patients (92%) and in eight patients (61%), CTS release was performed."

Adult cohort supports carpal tunnel syndrome as a common ML III manifestation.

Generalized osteoporosis FREQUENT Generalized osteoporosis (HP:0040160)

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0040160 | Generalized osteoporosis | Frequent (79-30%)"

Orphanet provides the phenotype association and frequency band.

🧬

Genetic Associations

1

GNPTAB biallelic pathogenic variants (Causative)

Autosomal recessive inheritance

Show evidence (2 references)

ORPHA:423461 SUPPORT Other

"GNPTAB | N-acetylglucosamine-1-phosphate transferase subunits alpha and beta | hgnc:29670 | Disease-causing germline mutation(s) (loss of function) in"

Orphanet records GNPTAB loss-of-function germline variants as disease-causing.

DOI:10.1136/jmg.2009.067736 SUPPORT Human Clinical

"Fifty-one pathogenic changes in GNPTAB are presented, including 42 novel mutations."

The 61-proband study supports GNPTAB variant heterogeneity.

💊

Treatments

5

Supportive multisystem surveillance and care

Action: supportive care MAXO:0000950

Supportive management includes low-impact therapy, monitoring for skeletal, bone-pain, cardiac, respiratory, and airway/anesthesia complications, and follow-up frequency tailored to disease course.

Target Phenotypes: Bone pain ↗ Loss of ambulation ↗ Recurrent otitis media ↗ Recurrent upper respiratory tract infections ↗ Congestive heart failure ↗

Show evidence (1 reference)

PMID:20301730 SUPPORT Human Clinical

"annual routine follow-up visits after age six years unless bone pain, deteriorating ambulation, and/or cardiac and respiratory monitoring need more frequent attention."

GeneReviews supports longitudinal supportive surveillance for bone, ambulation, cardiac, and respiratory complications.

Physical therapy for joint stiffness and contractures

Action: physical therapy MAXO:0000011

Low-impact physical therapy and physiotherapy are used to maintain mobility and manage joint stiffness, hip or knee contractures, and functional limitations.

Target Phenotypes: Joint stiffness ↗ Flexion contracture ↗

Show evidence (2 references)

PMID:20301730 SUPPORT Human Clinical

"Low-impact physical therapy is usually well tolerated."

GeneReviews supports low-impact physical therapy for manifestations.

PMID:10472261 SUPPORT Human Clinical

"joint stiffness and hip and knee contractures were managed by physiotherapy."

Orthopedic case series supports physiotherapy for joint stiffness and contractures.

Orthopedic and carpal tunnel surgery

Action: surgical procedure MAXO:0000004

Surgical management may include carpal tunnel release and orthopedic procedures such as hip replacement for severe skeletal disease, with anesthesia planning in tertiary centers because airway risk can be elevated.

Target Phenotypes: Constrictive median neuropathy ↗ Bone pain ↗

Show evidence (2 references)

PMID:10472261 SUPPORT Human Clinical

"Carpal tunnel syndrome was treated surgically"

Orthopedic case series supports carpal tunnel surgery.

PMID:29704188 SUPPORT Human Clinical

"All patients underwent multiple orthopaedic surgical interventions as early as the second or third decades of life, of which total hip replacement (THR) was the most common procedure (61% of patients)."

Adult cohort supports orthopedic surgical intervention, especially total hip replacement.

Intravenous pamidronate for bone pain

Action: pharmacotherapy MAXO:0000058

Agent: pamidronate ↗

Intravenous pamidronate has been reported as an adjunctive bisphosphonate treatment for ML III osteodystrophy and bone pain, improving pain and mobility in two siblings despite incomplete biochemical and histologic correction.

Mechanism Target:

MODULATES Skeletal and joint degeneration — Pamidronate targets high-turnover bone disease and bone pain downstream of ML III osteodystrophy.

Show evidence (1 reference)

PMID:12705498 SUPPORT Human Clinical

"Biochemical indices of bone turnover were increased"

The treatment study identifies elevated bone turnover as the therapeutic target.

Target Phenotypes: Bone pain ↗ Generalized osteoporosis ↗

Show evidence (2 references)

PMID:12705498 SUPPORT Human Clinical

"Intravenous pamidronate treatment given monthly for a year was well tolerated and produced dramatic clinical effects, with reduction in bone pain and improvements in mobility"

Study reports symptomatic improvement after intravenous pamidronate.

PMID:12705498 SUPPORT Human Clinical

"Bisphosphonate therapy may have an important role in the management of bone pain in ML III"

Study conclusion supports bisphosphonates as bone-pain management in ML III.

Genetic counseling

Action: genetic counseling MAXO:0000079

Genetic counseling informs recurrence risk, carrier testing, and prenatal or family-based testing when familial GNPTAB pathogenic variants are known.

Show evidence (1 reference)

PMID:20301730 SUPPORT Human Clinical

"Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants in the family are known."

GeneReviews supports genetic counseling for carrier and prenatal risk assessment.

🔬

Biochemical Markers

4

Diagnostic lysosomal hydrolase disparity (ABNORMAL)

Context: Diagnostic enzyme activity profile

Pathograph Readouts

Readout Of Lysosomal hydrolase mistargeting and secretion Positive Diagnostic

A larger extracellular-to-intracellular lysosomal hydrolase disparity reports more severe lysosomal enzyme mistargeting.

Show evidence (2 references)

PMID:20301730 SUPPORT Human Clinical

"the activity of nearly all lysosomal hydrolases is up to tenfold higher in plasma and other body fluids than in normal controls because of inadequate targeting to lysosomes."

GeneReviews supports elevated plasma and body-fluid lysosomal hydrolases.

PMID:20367762 SUPPORT Human Clinical

"markedly elevated plasma lysosomal hydrolases and the demonstration of markedly deficient white cell enzymes in cultured skin fibroblast."

Natural-history cohort supports the diagnostic hydrolase disparity.

GlcNAc-1-phosphotransferase activity (DECREASED)

Context: Diagnostic enzyme activity assay

Pathograph Readouts

Readout Of GNPTAB phosphotransferase deficiency Negative Diagnostic

Lower measured GlcNAc-1-phosphotransferase activity reports the primary GNPTAB alpha/beta enzyme defect.

Show evidence (2 references)

PMID:20301730 SUPPORT Human Clinical

"Significant deficiency (1%-10% of normal) of the activity of the enzyme UDP-N-acetylglucosamine: lysosomal hydrolase N-acetylglucosamine-1-phosphotransferase (GNPTA), encoded by GNPTAB, confirms the diagnosis."

GeneReviews supports decreased GlcNAc-1-phosphotransferase activity as confirmatory.

DOI:10.1136/jmg.2009.067736 SUPPORT Human Clinical

"ML III retains a low level of phosphotransferase activity because of at least one missense or splice site mutation."

Cohort data support residual but decreased phosphotransferase activity in ML III.

Urinary oligosaccharides (INCREASED)

Context: Urine screening biomarker

Pathograph Readouts

Readout Of Intracellular glycosphingolipid and glycosaminoglycan storage Positive Diagnostic

Excess urinary oligosaccharide excretion is a nonspecific urine readout of impaired lysosomal glycan degradation.

Show evidence (2 references)

PMID:20301730 SUPPORT Human Clinical

"Urinary excretion of oligosaccharides (OSs), a nonspecific finding, is often excessive."

GeneReviews supports excessive urinary oligosaccharide excretion.

ORPHA:423461 SUPPORT Other

"HP:0010471 | Oligosacchariduria | Very frequent (99-80%)"

Orphanet lists oligosacchariduria as very frequent.

Urinary keratan sulfate (INCREASED)

Context: Urine glycosaminoglycan biomarker

Pathograph Readouts

Readout Of Intracellular glycosphingolipid and glycosaminoglycan storage Positive Diagnostic

Urinary keratan sulfate excretion reports excess glycosaminoglycan storage and turnover in this lysosomal storage disorder.

Show evidence (1 reference)

ORPHA:423461 SUPPORT Other

"HP:0012069 | Keratan sulfate excretion in urine | Frequent (79-30%)"

Orphanet provides the urinary keratan sulfate biomarker association.

{ }

Source YAML

click to show

name: Mucolipidosis Type III Alpha/Beta
category: Mendelian
creation_date: "2026-05-08T04:37:03Z"
updated_date: "2026-05-18T05:01:47Z"
synonyms:
- ML III alpha/beta
- Pseudo-Hurler polydystrophy
description: >
  Mucolipidosis type III alpha/beta is an autosomal recessive lysosomal
  trafficking disorder caused by biallelic pathogenic variants in GNPTAB.
  Reduced UDP-N-acetylglucosamine-1-phosphotransferase activity impairs
  mannose-6-phosphate marking of lysosomal hydrolases, causing defective
  lysosomal targeting, extracellular leakage of lysosomal enzymes, and
  intracellular storage of incompletely degraded glycosaminoglycans and
  sphingolipids. The alpha/beta subtype is usually attenuated compared with
  mucolipidosis II, with childhood-onset growth slowing, joint stiffness and
  pain, dysostosis multiplex, osteoporosis and osteoarthritis, mild facial
  coarsening, conductive hearing impairment or recurrent otitis media, and
  cardiac valve disease.
disease_term:
  preferred_term: mucolipidosis type III, alpha/beta
  term:
    id: MONDO:0018931
    label: mucolipidosis type III, alpha/beta
parents:
- Familial mucolipidosis
- GNPTAB-mucolipidosis
- Lysosomal storage disease with skeletal involvement
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0018931
      label: mucolipidosis type III, alpha/beta
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet ORPHA:423461
    mapping_justification: >
      Orphanet ORPHA:423461 lists MONDO:0018931 as an exact cross-reference for
      mucolipidosis type III alpha/beta.
external_assertions:
- name: Orphanet mucolipidosis type III alpha/beta record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:423461
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423461
  description: >
    Orphanet's ORPHA:423461 structured record for mucolipidosis type III
    alpha/beta includes the exact MONDO and OMIM cross-references, autosomal
    recessive inheritance, GNPTAB disease-gene assertion, definition,
    epidemiology, and HPO phenotype rows used in this entry.
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0018931 | Exact"
    explanation: Orphanet maps ORPHA:423461 exactly to the MONDO identifier used by this entry.
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:252600 | Exact"
    explanation: Orphanet lists OMIM:252600 as an exact external cross-reference.
definitions:
- name: Orphanet mucolipidosis type III alpha/beta definition
  definition_type: OTHER
  description: >
    A lysosomal disorder characterized by early-childhood growth slowing, joint
    stiffness and pain, gradual facial coarsening, moderate developmental delay,
    and mild intellectual disability in most patients.
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mucolipidosis III alpha/beta (MLIII alpha/beta) is a lysosomal disorder characterized by progressive slowing of the growth rate from early childhood, stiffness and pain in joints, gradual coarsening of facial features, moderate developmental delay and mild intellectual disability in most patients."
    explanation: Orphanet defines the disorder and its core clinical manifestations.
inheritance:
- name: Autosomal recessive inheritance
  description: Mucolipidosis type III alpha/beta is inherited in an autosomal recessive pattern.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance.
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ML III alpha/beta is inherited in an autosomal recessive manner."
    explanation: GeneReviews states autosomal recessive inheritance for ML III alpha/beta.
prevalence:
- population: Worldwide
  percentage: 1-5 / 10,000 point prevalence
  notes: >
    Orphanet lists a worldwide point-prevalence band of 1-5 per 10,000 for
    ORPHA:423461, citing PMID:20301730. Published adult cohorts and case
    reports describe ML III as rare, but population-level estimates remain
    source-dependent.
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-5 / 10 000 | Worldwide | Point prevalence | PMID:20301730"
    explanation: Orphanet provides the worldwide point-prevalence table row for this subtype.
progression:
- phase: Childhood-onset attenuated lysosomal storage course
  age_range: Childhood to adulthood
  notes: >
    ML III alpha/beta is typically milder and slower than ML II, with clinical
    onset around early childhood, growth slowing after early school age, and
    progressive skeletal, joint, and cardiopulmonary complications through
    adolescence and adulthood.
  evidence:
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a slowly progressive disorder with clinical onset at approximately age three years"
    explanation: GeneReviews supports childhood onset and slow progression.
  - reference: DOI:10.1136/jmg.2009.067736
    reference_title: "Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ML III retains a low level of phosphotransferase activity because of at least one missense or splice site mutation. The phenotype is milder, with minimal delays in milestones, the appearance of facial coarsening by early school age, and slowing of growth after the age of 4 years."
    explanation: The 61-proband study supports residual activity and an attenuated ML III clinical course.
pathophysiology:
- name: GNPTAB phosphotransferase deficiency
  description: >
    Biallelic pathogenic GNPTAB variants reduce activity of the alpha/beta
    subunits of UDP-N-acetylglucosamine-1-phosphotransferase, preventing normal
    synthesis of mannose-6-phosphate recognition markers on lysosomal hydrolases.
  genes:
  - preferred_term: GNPTAB
    term:
      id: hgnc:29670
      label: GNPTAB
  biological_processes:
  - preferred_term: protein targeting to lysosome
    modifier: DECREASED
    term:
      id: GO:0006622
      label: protein targeting to lysosome
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: DOI:10.1136/jmg.2009.067736
    reference_title: "Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disorders are caused by mutations in GNPTAB, which encodes two of three subunits of the heterohexameric enzyme, N-acetylglucosamine-1-phosphotransferase."
    explanation: The cohort directly links ML II/III alpha/beta to GNPTAB mutations and the phosphotransferase enzyme.
  - reference: PMID:19197337
    reference_title: "Mucolipidosis II and III alpha/beta: mutation analysis of 40 Japanese patients showed genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diseases caused by a deficiency of alpha and/or beta subunits of the enzyme N-acetylglucosamine-1-phosphotransferase, which is encoded by the GNPTAB gene."
    explanation: The Japanese cohort independently supports GNPTAB-encoded alpha/beta subunit deficiency.
  downstream:
  - target: Lysosomal hydrolase mistargeting and secretion
    description: Loss of phosphotransferase activity impairs mannose-6-phosphate recognition-marker synthesis on lysosomal hydrolases.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.1136/jmg.2009.067736
      reference_title: "Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the essential mannose 6-phosphate recognition marker is not synthesised on to lysosomal hydrolases and other glycoproteins."
      explanation: GNPTAB disease directly impairs the recognition marker needed for lysosomal hydrolase targeting.
  - target: GlcNAc-1-phosphotransferase activity
    description: GNPTAB alpha/beta subunit deficiency is measured as markedly decreased GlcNAc-1-phosphotransferase activity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301730
      reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Significant deficiency (1%-10% of normal) of the activity of the enzyme UDP-N-acetylglucosamine: lysosomal hydrolase N-acetylglucosamine-1-phosphotransferase (GNPTA), encoded by GNPTAB, confirms the diagnosis."
      explanation: GeneReviews supports that the molecular enzyme defect is detected as severely decreased phosphotransferase activity.
- name: Lysosomal hydrolase mistargeting and secretion
  description: >
    Hydrolases lacking mannose-6-phosphate tags fail to localize efficiently to
    lysosomes, producing elevated extracellular lysosomal enzyme activities and
    deficient intracellular lysosomal degradation.
  biological_processes:
  - preferred_term: protein localization to lysosome
    modifier: DECREASED
    term:
      id: GO:0061462
      label: protein localization to lysosome
  - preferred_term: lysosomal transport
    modifier: DECREASED
    term:
      id: GO:0007041
      label: lysosomal transport
  cellular_components:
  - preferred_term: lysosomal lumen
    term:
      id: GO:0043202
      label: lysosomal lumen
  evidence:
  - reference: PMID:21466370
    reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Without these important recognition markers, lysosomal enzymes are not transported to the lysosomes; instead, they leak out of cells, and the serum levels of these enzymes are higher than normal."
    explanation: Autopsy review directly explains lysosomal hydrolase mistargeting and extracellular leakage.
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the activity of nearly all lysosomal hydrolases is up to tenfold higher in plasma and other body fluids than in normal controls because of inadequate targeting to lysosomes."
    explanation: GeneReviews supports elevated plasma and fluid hydrolases due to inadequate lysosomal targeting.
  downstream:
  - target: Intracellular glycosphingolipid and glycosaminoglycan storage
    description: Failed lysosomal delivery of degradative enzymes leaves macromolecules incompletely degraded inside cells.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21466370
      reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Macromolecules are thus incompletely degraded and subsequently accumulate in tissues."
      explanation: Mistargeting of lysosomal enzymes directly causes intracellular macromolecule accumulation.
  - target: Diagnostic lysosomal hydrolase disparity
    description: The secretion/localization defect produces elevated plasma hydrolases and deficient intracellular enzyme activity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20367762
      reference_title: The natural history and osteodystrophy of mucolipidosis types II and III.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "markedly elevated plasma lysosomal hydrolases and the demonstration of markedly deficient white cell enzymes in cultured skin fibroblast."
      explanation: Patient diagnostic testing shows the expected hydrolase disparity.
- name: Intracellular glycosphingolipid and glycosaminoglycan storage
  description: >
    Incompletely degraded glycosaminoglycans, sphingolipids, and related
    macromolecules accumulate in lysosomes across connective tissue, cardiac,
    neural, cartilage, and fibroblast-rich tissues.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  biological_processes:
  - preferred_term: glycosaminoglycan catabolic process
    modifier: DECREASED
    term:
      id: GO:0006027
      label: glycosaminoglycan catabolic process
  - preferred_term: glycosphingolipid catabolic process
    modifier: DECREASED
    term:
      id: GO:0046479
      label: glycosphingolipid catabolic process
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: PMID:20367762
    reference_title: The natural history and osteodystrophy of mucolipidosis types II and III.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "global deficiencies of lysosomal degradative enzymes with concomitant intracellular accumulation of both partly degraded glycosaminoglycans and sphingolipids."
    explanation: The natural-history study links defective hydrolase targeting to intracellular storage products.
  - reference: PMID:21466370
    reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Accumulation of mucopolysaccharides along with lipids within lysosomes of patients with mucolipidosis is the characteristic abnormality."
    explanation: Autopsy review identifies lysosomal mucopolysaccharide and lipid storage as characteristic.
  downstream:
  - target: Skeletal and joint degeneration
    description: Connective-tissue and skeletal storage contributes to the dominant skeletal and joint phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21466370
      reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mucolipidosis type III is milder than other forms of mucolipidosis, and its clinical features most significantly involve abnormalities in cartilage and bone with a mild coarsening of facial features."
      explanation: The autopsy review links ML III to prominent cartilage and bone abnormalities.
  - target: Cardiac valve and myocardial involvement
    description: Cardiac and valvular tissues can accumulate storage material, contributing to valve and myocardial disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:32818557
      reference_title: A Rare Manifestation of Right Ventricular Dysfunction in an Adult Patient With Mucolipidosis Type III alpha/beta.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The resultant intralysosomal accumulation of partly degraded mucopolysaccharides and sphingolipids causes multiple-organ damage, including the heart."
      explanation: Cardiology case report links storage to cardiac organ damage.
  - target: Somatic growth impairment
    description: Residual ML III storage disease impairs childhood growth, producing postnatal growth slowing and short stature.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: DOI:10.1136/jmg.2009.067736
      reference_title: "Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "ML III retains a low level of phosphotransferase activity because of at least one missense or splice site mutation. The phenotype is milder, with minimal delays in milestones, the appearance of facial coarsening by early school age, and slowing of growth after the age of 4 years."
      explanation: The large genotype-phenotype study links residual phosphotransferase activity in ML III to an attenuated phenotype with later growth slowing.
  - target: Craniofacial and connective tissue involvement
    description: Storage in fibroblast-rich connective tissues contributes to facial, gingival, skin, abdominal wall, and ocular surface manifestations.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21466370
      reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Overall, the electron microscopic exam was significant for an increased number of intracellular lysosomal granules, particularly in the brain but also in cells of the heart, mitral valve, cartilage, and fibroblasts within the skin and liver."
      explanation: Autopsy demonstrates storage granules in skin fibroblasts and other connective-tissue-rich sites.
  - target: Airway, middle ear, and hearing involvement
    description: Cartilage, airway, middle-ear, and respiratory involvement connects lysosomal storage to recurrent otitis, hearing impairment, hoarse voice, and recurrent respiratory infections.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21466370
      reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Her disease manifested most notably as multiple bone and cartilage problems with tracheal and bronchial malacia."
      explanation: The autopsy case links ML III storage disease to cartilage and airway malacia.
  - target: Mild CNS storage and cognitive involvement
    description: Mild lysosomal storage in neurons and glia provides a mechanistic branch for developmental delay and cognitive impairment.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21466370
      reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Electron microscopy of cerebral cortex sections showed scattered, diffuse vesicular cytoplasmic lysosomal granules in glia and neurons"
      explanation: Autopsy demonstrates CNS lysosomal storage in neurons and glia.
  - target: Oligosacchariduria
    description: Impaired lysosomal glycan degradation produces excessive urinary oligosaccharide excretion.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301730
      reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Urinary excretion of oligosaccharides (OSs), a nonspecific finding, is often excessive."
      explanation: GeneReviews supports oligosacchariduria as an excessive urine excretion readout of ML III alpha/beta.
  - target: Keratan sulfate excretion in urine
    description: Glycosaminoglycan storage and turnover can present as urinary keratan sulfate excretion.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0012069 | Keratan sulfate excretion in urine | Frequent (79-30%)"
      explanation: Orphanet lists urinary keratan sulfate excretion as a frequent ML III alpha/beta phenotype.
- name: Skeletal and joint degeneration
  description: >
    ML III skeletal disease combines dysostosis multiplex, osteodystrophy,
    progressive osteoarthritis, cartilage destruction, bone lesions, bone pain,
    joint stiffness, and entrapment neuropathy.
  cell_types:
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  - preferred_term: osteoclast
    term:
      id: CL:0000092
      label: osteoclast
  evidence:
  - reference: PMID:29704188
    reference_title: Mucolipidosis type III, a series of adult patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients had dysostosis multiplex and progressive secondary osteoarthritis, characterised by cartilage destruction and bone lesions in multiple joints."
    explanation: Adult cohort supports progressive skeletal and joint degeneration in ML III.
  - reference: PMID:12705498
    reference_title: The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Biochemical indices of bone turnover were increased, and transiliac bone biopsy demonstrated both trabecular osteopenia and marked subperiosteal bone resorption."
    explanation: The pamidronate study supports osteodystrophy with high bone turnover and osteopenia.
  downstream:
  - target: Joint stiffness
    description: Joint stiffness is a very frequent skeletal/joint manifestation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20367762
      reference_title: The natural history and osteodystrophy of mucolipidosis types II and III.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "All patients had progressive joint stiffness."
      explanation: Natural-history cohort supports joint stiffness as a direct skeletal/joint manifestation.
  - target: Bone pain
    description: Bone pain is a frequent clinical consequence of skeletal disease.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:12705498
      reference_title: The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "reduction in bone pain and improvements in mobility"
      explanation: Pamidronate-treated siblings had ML III osteodystrophy with clinically tracked bone pain.
  - target: Dysostosis multiplex
    description: Dysostosis multiplex is part of the radiographic skeletal phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29704188
      reference_title: Mucolipidosis type III, a series of adult patients.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "All patients had dysostosis multiplex and progressive secondary osteoarthritis, characterised by cartilage destruction and bone lesions in multiple joints."
      explanation: Adult cohort directly links ML III skeletal degeneration with dysostosis multiplex and osteoarthritic joint disease.
  - target: Generalized osteoporosis
    description: Osteopenia and osteoporosis are part of the osteodystrophy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301730
      reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Pain from osteoporosis that is clinically and radiologically apparent in childhood becomes more severe from adolescence."
      explanation: GeneReviews directly supports clinically and radiologically apparent osteoporosis in ML III alpha/beta.
  - target: Kyphoscoliosis
    description: Spinal skeletal involvement includes thoracolumbar kyphosis and scoliosis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21466370
      reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Prominent kyphosis and scoliosis of the spine were noted"
      explanation: Autopsy examination directly supports kyphotic and scoliotic spinal involvement.
  - target: Osteolysis
    description: Progressive osteodystrophy includes severe carpal and femoral osteolysis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20367762
      reference_title: The natural history and osteodystrophy of mucolipidosis types II and III.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "consistent with severe carpal osteolysis. Similarly there was severe osteolysis of the femoral heads and femoral necks."
      explanation: Natural-history radiographs directly support osteolysis as part of the skeletal disease.
  - target: Constrictive median neuropathy
    description: Carpal tunnel syndrome is common in adults with ML III.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29704188
      reference_title: Mucolipidosis type III, a series of adult patients.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Carpal tunnel syndrome (CTS) was found in 12 patients (92%) and in eight patients (61%), CTS release was performed."
      explanation: Adult cohort supports carpal tunnel syndrome as a frequent consequence requiring release surgery.
  - target: Loss of ambulation
    description: Progressive skeletal and joint disease can impair mobility and produce wheelchair dependence.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29704188
      reference_title: Mucolipidosis type III, a series of adult patients.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Six patients (46%) needed help with activities of daily living (ADL) or were wheelchair-dependent."
      explanation: Adult cohort supports impaired mobility and wheelchair dependence downstream of severe skeletal disease.
  - target: Flexion contracture
    description: Joint disease causes hip, knee, and other flexion contractures that require physiotherapy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:10472261
      reference_title: Orthopaedic management in four cases of mucolipidosis type III.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "joint stiffness and hip and knee contractures were managed by physiotherapy."
      explanation: Orthopedic case series directly links ML III joint disease to hip and knee contractures.
  - target: Gait disturbance
    description: Progressive skeletal and joint disease disturbs gait and mobility.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001288 | Gait disturbance | Frequent (79-30%)"
      explanation: Orphanet lists gait disturbance as a frequent ML III alpha/beta manifestation.
  - target: Short neck
    description: Skeletal and connective tissue involvement includes short neck morphology.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21466370
      reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Prominent kyphosis and scoliosis of the spine were noted, and her neck was short."
      explanation: Autopsy examination directly documents short neck with spinal skeletal abnormalities.
- name: Cardiac valve and myocardial involvement
  description: >
    Lysosomal storage in cardiovascular tissues produces valve thickening and
    insufficiency, most often involving mitral and aortic valves, and can rarely
    involve myocardium or right ventricular function.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  evidence:
  - reference: PMID:32818557
    reference_title: A Rare Manifestation of Right Ventricular Dysfunction in an Adult Patient With Mucolipidosis Type III alpha/beta.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most documented cardiac manifestation is the thickening and insufficiency of mitral and aortic valves, but there are very few reports about the myocardial involvement."
    explanation: Cardiology case report supports valve insufficiency and rare myocardial involvement in ML III alpha/beta.
  - reference: PMID:21466370
    reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Valvular cardiac disease has also been well established in ML III."
    explanation: Autopsy review supports established valvular cardiac disease.
  downstream:
  - target: Mitral regurgitation
    description: Mitral valve insufficiency is a frequent cardiac manifestation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32818557
      reference_title: A Rare Manifestation of Right Ventricular Dysfunction in an Adult Patient With Mucolipidosis Type III alpha/beta.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The most documented cardiac manifestation is the thickening and insufficiency of mitral and aortic valves, but there are very few reports about the myocardial involvement."
      explanation: Cardiology case report supports mitral valve insufficiency as a documented cardiac manifestation.
  - target: Aortic regurgitation
    description: Aortic valve insufficiency is a frequent cardiac manifestation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32818557
      reference_title: A Rare Manifestation of Right Ventricular Dysfunction in an Adult Patient With Mucolipidosis Type III alpha/beta.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The most documented cardiac manifestation is the thickening and insufficiency of mitral and aortic valves, but there are very few reports about the myocardial involvement."
      explanation: Cardiology case report supports aortic valve insufficiency as a documented cardiac manifestation.
  - target: Congestive heart failure
    description: Progressive cardiorespiratory disease can culminate in heart failure.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301730
      reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cardiorespiratory complications (restrictive lung disease, thickening and insufficiency of the mitral and aortic valves, left and/or right ventricular hypertrophy) are common causes of death, typically in early to middle adulthood."
      explanation: GeneReviews links cardiorespiratory complications and ventricular hypertrophy to fatal adult outcomes.
  - target: Right ventricular hypertrophy
    description: Right ventricular structural involvement is an occasional cardiac feature.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301730
      reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cardiorespiratory complications (restrictive lung disease, thickening and insufficiency of the mitral and aortic valves, left and/or right ventricular hypertrophy) are common causes of death, typically in early to middle adulthood."
      explanation: GeneReviews lists right ventricular hypertrophy among cardiorespiratory complications.
- name: Somatic growth impairment
  description: >
    Childhood-onset ML III alpha/beta causes slowing of growth after early
    childhood and produces persistent short stature.
  evidence:
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a slowly progressive disorder with clinical onset at approximately age three years, is characterized by slow growth rate and subnormal stature"
    explanation: GeneReviews supports slow growth rate and subnormal stature in ML III alpha/beta.
  - reference: DOI:10.1136/jmg.2009.067736
    reference_title: "Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ML III retains a low level of phosphotransferase activity because of at least one missense or splice site mutation. The phenotype is milder, with minimal delays in milestones, the appearance of facial coarsening by early school age, and slowing of growth after the age of 4 years."
    explanation: Large cohort supports growth slowing in the attenuated ML III phenotype.
  downstream:
  - target: Short stature
    description: Persistent postnatal growth slowing produces short stature.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0004322 | Short stature | Very frequent (99-80%)"
      explanation: Orphanet lists short stature as a very frequent phenotype.
  - target: Postnatal growth retardation
    description: Growth slowing after early childhood is captured clinically as postnatal growth retardation.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0008897 | Postnatal growth retardation | Very frequent (99-80%)"
      explanation: Orphanet lists postnatal growth retardation as a very frequent phenotype.
- name: Craniofacial and connective tissue involvement
  description: >
    Lysosomal storage in fibroblast-rich connective tissues and related
    Hurler-like tissue involvement produces facial coarsening, gingival
    overgrowth, thickened skin, abdominal wall findings, and ocular surface
    manifestations.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  evidence:
  - reference: PMID:21466370
    reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The external exam revealed a patient of short stature (138 cm) weighing 43 kg with slightly coarsened facial features. She appeared younger than her stated age with pale white to waxy skin."
    explanation: Autopsy examination supports facial and skin involvement in ML III.
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mucolipidosis III alpha/beta (MLIII alpha/beta) is a lysosomal disorder characterized by progressive slowing of the growth rate from early childhood, stiffness and pain in joints, gradual coarsening of facial features, moderate developmental delay and mild intellectual disability in most patients."
    explanation: Orphanet definition supports gradual facial coarsening as a core manifestation.
  downstream:
  - target: Gingival overgrowth
    description: Connective-tissue storage can produce gingival enlargement.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000212 | Gingival overgrowth | Frequent (79-30%)"
      explanation: Orphanet lists gingival overgrowth as a frequent manifestation.
  - target: Coarse facial features
    description: Facial connective-tissue involvement produces gradual facial coarsening.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000280 | Coarse facial features | Frequent (79-30%)"
      explanation: Orphanet lists coarse facial features as a frequent manifestation.
  - target: Epicanthus
    description: Craniofacial involvement includes epicanthal folds.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000286 | Epicanthus | Frequent (79-30%)"
      explanation: Orphanet lists epicanthus as a frequent manifestation.
  - target: Full cheeks
    description: Craniofacial involvement includes full cheeks.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000293 | Full cheeks | Frequent (79-30%)"
      explanation: Orphanet lists full cheeks as a frequent manifestation.
  - target: Thickened skin
    description: Skin fibroblast storage is consistent with thickened skin.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001072 | Thickened skin | Frequent (79-30%)"
      explanation: Orphanet lists thickened skin as a frequent manifestation.
  - target: Umbilical hernia
    description: Connective-tissue and abdominal-wall involvement can produce umbilical hernia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001537 | Umbilical hernia | Occasional (29-5%)"
      explanation: Orphanet lists umbilical hernia as an occasional manifestation.
  - target: Diastasis recti
    description: Abdominal-wall connective-tissue involvement can produce diastasis recti.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001540 | Diastasis recti | Occasional (29-5%)"
      explanation: Orphanet lists diastasis recti as an occasional manifestation.
  - target: Abdominal wall muscle weakness
    description: Abdominal-wall involvement can manifest as abdominal wall muscle weakness.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0009023 | Abdominal wall muscle weakness | Frequent (79-30%)"
      explanation: Orphanet lists abdominal wall muscle weakness as a frequent manifestation.
  - target: Depressed nasal bridge
    description: Craniofacial involvement includes depressed nasal bridge.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0005280 | Depressed nasal bridge | Frequent (79-30%)"
      explanation: Orphanet lists depressed nasal bridge as a frequent manifestation.
  - target: Proptosis
    description: Craniofacial and orbital connective-tissue involvement can present as proptosis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000520 | Proptosis | Very rare (<4-1%)"
      explanation: Orphanet lists proptosis as a very rare manifestation.
  - target: Corneal opacity
    description: Ocular connective-tissue involvement can produce mild corneal clouding or opacity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21466370
      reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Other clinical characteristics include mild coarsening of facial features, mild corneal clouding, and valvular heart disease, and about half of patients experience mild intellectual disability."
      explanation: Autopsy review lists mild corneal clouding among ML III clinical characteristics.
- name: Airway, middle ear, and hearing involvement
  description: >
    ML III alpha/beta affects airway cartilage and recurrent middle-ear disease,
    producing otitis media, hearing impairment, hoarse voice, and recurrent
    respiratory infections.
  cell_types:
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  evidence:
  - reference: PMID:20367762
    reference_title: The natural history and osteodystrophy of mucolipidosis types II and III.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chronic otitis media was present in 7/10 patients."
    explanation: Natural-history cohort supports frequent middle-ear involvement.
  - reference: PMID:21466370
    reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The lungs revealed patchy fibrosis and prominent chronic inflammation with increased intra-alveolar macrophages and lymphocytes as well as evidence of resolving aspiration pneumonia."
    explanation: Autopsy supports clinically important respiratory involvement.
  downstream:
  - target: Recurrent otitis media
    description: Middle-ear involvement causes recurrent otitis media.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301730
      reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Myringotomy tube placement may be indicated in the treatment of recurrent otitis media."
      explanation: GeneReviews supports recurrent otitis media as a treated ML III manifestation.
  - target: Conductive hearing impairment
    description: Recurrent middle-ear disease can cause conductive hearing impairment.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000405 | Conductive hearing impairment | Frequent (79-30%)"
      explanation: Orphanet lists conductive hearing impairment as a frequent manifestation.
  - target: Sensorineural hearing impairment
    description: Less commonly, hearing involvement includes sensorineural hearing impairment.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000407 | Sensorineural hearing impairment | Very rare (<4-1%)"
      explanation: Orphanet lists sensorineural hearing impairment as a very rare manifestation.
  - target: Hoarse voice
    description: Airway and laryngeal involvement can present with hoarse voice.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001609 | Hoarse voice | Occasional (29-5%)"
      explanation: Orphanet lists hoarse voice as an occasional manifestation.
  - target: Recurrent upper respiratory tract infections
    description: Airway involvement predisposes to recurrent respiratory infections.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002788 | Recurrent upper respiratory tract infections | Occasional (29-5%)"
      explanation: Orphanet lists recurrent upper respiratory tract infections as an occasional manifestation.
- name: Mild CNS storage and cognitive involvement
  description: >
    Attenuated neuronal and glial lysosomal storage in ML III alpha/beta can
    accompany mild developmental or cognitive impairment.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: glial cell
    term:
      id: CL:0000125
      label: glial cell
  evidence:
  - reference: PMID:21466370
    reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "By electron microscopy there were scattered, diffuse vesicular cytoplasmic granules in neurons and glia and an increase in lysosomal structures with fine electron lucent granularity in the above tissue types."
    explanation: Autopsy documents neuronal and glial lysosomal storage in ML III alpha/beta.
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gradual mild coarsening of facial features; and normal to mildly impaired cognitive development."
    explanation: GeneReviews supports mild cognitive involvement in some patients.
  downstream:
  - target: Cognitive impairment
    description: Mild CNS storage and development effects can present as cognitive impairment.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:423461
      reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0100543 | Cognitive impairment | Occasional (29-5%)"
      explanation: Orphanet lists cognitive impairment as an occasional phenotype.
phenotypes:
- name: Gingival overgrowth
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Gingival overgrowth
    term:
      id: HP:0000212
      label: Gingival overgrowth
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000212 | Gingival overgrowth | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Coarse facial features
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Coarse facial features
    term:
      id: HP:0000280
      label: Coarse facial features
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000280 | Coarse facial features | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Epicanthus
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Epicanthus
    term:
      id: HP:0000286
      label: Epicanthus
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000286 | Epicanthus | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Full cheeks
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Full cheeks
    term:
      id: HP:0000293
      label: Full cheeks
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000293 | Full cheeks | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Recurrent otitis media
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Recurrent otitis media
    term:
      id: HP:0000403
      label: Recurrent otitis media
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000403 | Recurrent otitis media | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Conductive hearing impairment
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Conductive hearing impairment
    term:
      id: HP:0000405
      label: Conductive hearing impairment
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000405 | Conductive hearing impairment | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Sensorineural hearing impairment
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000407 | Sensorineural hearing impairment | Very rare (<4-1%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Short neck
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Short neck
    term:
      id: HP:0000470
      label: Short neck
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000470 | Short neck | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Proptosis
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Proptosis
    term:
      id: HP:0000520
      label: Proptosis
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000520 | Proptosis | Very rare (<4-1%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Dysostosis multiplex
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dysostosis multiplex
    term:
      id: HP:0000943
      label: Dysostosis multiplex
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000943 | Dysostosis multiplex | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Thickened skin
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Thickened skin
    term:
      id: HP:0001072
      label: Thickened skin
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001072 | Thickened skin | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Gait disturbance
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001288 | Gait disturbance | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Flexion contracture
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Flexion contracture
    term:
      id: HP:0001371
      label: Flexion contracture
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001371 | Flexion contracture | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Joint stiffness
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Joint stiffness
    term:
      id: HP:0001387
      label: Joint stiffness
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001387 | Joint stiffness | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
  - reference: PMID:10472261
    reference_title: Orthopaedic management in four cases of mucolipidosis type III.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Their main symptoms were carpal tunnel syndrome, trigger fingers and generalized joint stiffness."
    explanation: Orthopedic case series independently supports generalized joint stiffness.
- name: Umbilical hernia
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Umbilical hernia
    term:
      id: HP:0001537
      label: Umbilical hernia
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001537 | Umbilical hernia | Occasional (29-5%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Diastasis recti
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Diastasis recti
    term:
      id: HP:0001540
      label: Diastasis recti
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001540 | Diastasis recti | Occasional (29-5%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Hoarse voice
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Hoarse voice
    term:
      id: HP:0001609
      label: Hoarse voice
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001609 | Hoarse voice | Occasional (29-5%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Congestive heart failure
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001635 | Congestive heart failure | Occasional (29-5%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Mitral regurgitation
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Mitral regurgitation
    term:
      id: HP:0001653
      label: Mitral regurgitation
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001653 | Mitral regurgitation | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Aortic regurgitation
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Aortic regurgitation
    term:
      id: HP:0001659
      label: Aortic regurgitation
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001659 | Aortic regurgitation | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Right ventricular hypertrophy
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Right ventricular hypertrophy
    term:
      id: HP:0001667
      label: Right ventricular hypertrophy
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001667 | Right ventricular hypertrophy | Occasional (29-5%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Loss of ambulation
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Loss of ambulation
    term:
      id: HP:0002505
      label: Loss of ambulation
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002505 | Loss of ambulation | Occasional (29-5%)"
    explanation: Orphanet provides the phenotype association and frequency band.
  - reference: PMID:29704188
    reference_title: Mucolipidosis type III, a series of adult patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Six patients (46%) needed help with activities of daily living (ADL) or were wheelchair-dependent."
    explanation: Adult cohort supports mobility loss or wheelchair dependence in a substantial subset.
- name: Bone pain
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Bone pain
    term:
      id: HP:0002653
      label: Bone pain
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002653 | Bone pain | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Kyphoscoliosis
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Kyphoscoliosis
    term:
      id: HP:0002751
      label: Kyphoscoliosis
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002751 | Kyphoscoliosis | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Recurrent upper respiratory tract infections
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Recurrent upper respiratory tract infections
    term:
      id: HP:0002788
      label: Recurrent upper respiratory tract infections
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002788 | Recurrent upper respiratory tract infections | Occasional (29-5%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Osteolysis
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Osteolysis
    term:
      id: HP:0002797
      label: Osteolysis
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002797 | Osteolysis | Occasional (29-5%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Short stature
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004322 | Short stature | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Depressed nasal bridge
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Depressed nasal bridge
    term:
      id: HP:0005280
      label: Depressed nasal bridge
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0005280 | Depressed nasal bridge | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Corneal opacity
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Corneal opacity
    term:
      id: HP:0007957
      label: Corneal opacity
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007957 | Corneal opacity | Occasional (29-5%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Postnatal growth retardation
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Postnatal growth retardation
    term:
      id: HP:0008897
      label: Postnatal growth retardation
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008897 | Postnatal growth retardation | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Abdominal wall muscle weakness
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abdominal wall muscle weakness
    term:
      id: HP:0009023
      label: Abdominal wall muscle weakness
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0009023 | Abdominal wall muscle weakness | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Oligosacchariduria
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Oligosacchariduria
    term:
      id: HP:0010471
      label: Oligosacchariduria
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0010471 | Oligosacchariduria | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Keratan sulfate excretion in urine
  frequency: FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Keratan sulfate excretion in urine
    term:
      id: HP:0012069
      label: Keratan sulfate excretion in urine
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012069 | Keratan sulfate excretion in urine | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Constrictive median neuropathy
  frequency: OCCASIONAL
  notes: >
    Orphanet records constrictive median neuropathy as occasional across ML III
    alpha/beta, while the adult cohort in PMID:29704188 reported carpal tunnel
    syndrome in 92% of adult patients, consistent with higher frequency after
    long-standing skeletal and joint disease.
  phenotype_term:
    preferred_term: Constrictive median neuropathy
    term:
      id: HP:0012185
      label: Constrictive median neuropathy
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012185 | Constrictive median neuropathy | Occasional (29-5%)"
    explanation: Orphanet provides the phenotype association and frequency band.
  - reference: PMID:29704188
    reference_title: Mucolipidosis type III, a series of adult patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Carpal tunnel syndrome (CTS) was found in 12 patients (92%) and in eight patients (61%), CTS release was performed."
    explanation: Adult cohort supports carpal tunnel syndrome as a common ML III manifestation.
- name: Generalized osteoporosis
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Generalized osteoporosis
    term:
      id: HP:0040160
      label: Generalized osteoporosis
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0040160 | Generalized osteoporosis | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- name: Cognitive impairment
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100543 | Cognitive impairment | Occasional (29-5%)"
    explanation: Orphanet provides the phenotype association and frequency band.
genetic:
- name: GNPTAB biallelic pathogenic variants
  association: Causative
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: GNPTAB
    term:
      id: hgnc:29670
      label: GNPTAB
  variant_origin: GERMLINE
  notes: >
    ML III alpha/beta is caused by GNPTAB variants that retain residual
    phosphotransferase activity, commonly including at least one missense or
    splice-site allele; this contrasts with near-total loss in ML II.
  inheritance:
  - name: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GNPTAB | N-acetylglucosamine-1-phosphate transferase subunits alpha and beta | hgnc:29670 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet records GNPTAB loss-of-function germline variants as disease-causing.
  - reference: DOI:10.1136/jmg.2009.067736
    reference_title: "Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fifty-one pathogenic changes in GNPTAB are presented, including 42 novel mutations."
    explanation: The 61-proband study supports GNPTAB variant heterogeneity.
biochemical:
- name: Diagnostic lysosomal hydrolase disparity
  presence: ABNORMAL
  readouts:
  - target: Lysosomal hydrolase mistargeting and secretion
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: A larger extracellular-to-intracellular lysosomal hydrolase disparity reports more severe lysosomal enzyme mistargeting.
  context: Diagnostic enzyme activity profile
  notes: >
    The trafficking defect produces increased lysosomal hydrolase activities in
    plasma or extracellular fluid with deficient intracellular activity in
    leukocytes or cultured fibroblasts.
  evidence:
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the activity of nearly all lysosomal hydrolases is up to tenfold higher in plasma and other body fluids than in normal controls because of inadequate targeting to lysosomes."
    explanation: GeneReviews supports elevated plasma and body-fluid lysosomal hydrolases.
  - reference: PMID:20367762
    reference_title: The natural history and osteodystrophy of mucolipidosis types II and III.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "markedly elevated plasma lysosomal hydrolases and the demonstration of markedly deficient white cell enzymes in cultured skin fibroblast."
    explanation: Natural-history cohort supports the diagnostic hydrolase disparity.
- name: GlcNAc-1-phosphotransferase activity
  presence: DECREASED
  readouts:
  - target: GNPTAB phosphotransferase deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Lower measured GlcNAc-1-phosphotransferase activity reports the primary GNPTAB alpha/beta enzyme defect.
  context: Diagnostic enzyme activity assay
  notes: >
    Residual UDP-N-acetylglucosamine:lysosomal hydrolase
    N-acetylglucosamine-1-phosphotransferase activity distinguishes the
    attenuated ML III alpha/beta phenotype from severe ML II alpha/beta.
  evidence:
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Significant deficiency (1%-10% of normal) of the activity of the enzyme UDP-N-acetylglucosamine: lysosomal hydrolase N-acetylglucosamine-1-phosphotransferase (GNPTA), encoded by GNPTAB, confirms the diagnosis."
    explanation: GeneReviews supports decreased GlcNAc-1-phosphotransferase activity as confirmatory.
  - reference: DOI:10.1136/jmg.2009.067736
    reference_title: "Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ML III retains a low level of phosphotransferase activity because of at least one missense or splice site mutation."
    explanation: Cohort data support residual but decreased phosphotransferase activity in ML III.
- name: Urinary oligosaccharides
  biomarker_term:
    preferred_term: oligosaccharide
    term:
      id: CHEBI:50699
      label: oligosaccharide
  presence: INCREASED
  readouts:
  - target: Intracellular glycosphingolipid and glycosaminoglycan storage
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Excess urinary oligosaccharide excretion is a nonspecific urine readout of impaired lysosomal glycan degradation.
  context: Urine screening biomarker
  notes: Urinary oligosaccharide excretion is common but nonspecific.
  evidence:
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Urinary excretion of oligosaccharides (OSs), a nonspecific finding, is often excessive."
    explanation: GeneReviews supports excessive urinary oligosaccharide excretion.
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0010471 | Oligosacchariduria | Very frequent (99-80%)"
    explanation: Orphanet lists oligosacchariduria as very frequent.
- name: Urinary keratan sulfate
  biomarker_term:
    preferred_term: keratan sulfate
    term:
      id: CHEBI:60924
      label: keratan sulfate
  presence: INCREASED
  readouts:
  - target: Intracellular glycosphingolipid and glycosaminoglycan storage
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Urinary keratan sulfate excretion reports excess glycosaminoglycan storage and turnover in this lysosomal storage disorder.
  context: Urine glycosaminoglycan biomarker
  notes: Orphanet records increased urinary keratan sulfate as a frequent phenotype.
  evidence:
  - reference: ORPHA:423461
    reference_title: Mucolipidosis type III alpha/beta (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012069 | Keratan sulfate excretion in urine | Frequent (79-30%)"
    explanation: Orphanet provides the urinary keratan sulfate biomarker association.
histopathology:
- name: Lysosomal granular storage inclusions
  description: >
    Autopsy and ultrastructural examination show increased lysosomal granules
    in brain, heart, mitral valve, cartilage, skin, and liver fibroblasts,
    consistent with multisystem lysosomal storage.
  evidence:
  - reference: PMID:21466370
    reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, the electron microscopic exam was significant for an increased number of intracellular lysosomal granules, particularly in the brain but also in cells of the heart, mitral valve, cartilage, and fibroblasts within the skin and liver."
    explanation: Autopsy directly documents multisystem intracellular lysosomal granules.
  - reference: PMID:21466370
    reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cartilage of the trachea was notable for disordered collagen deposition and increased cellularity. Some of the chondrocytes were enlarged with granular, vacuolated cytoplasm."
    explanation: Autopsy supports cartilage and chondrocyte storage pathology.
- name: Bone osteodystrophy
  description: >
    Bone histology and imaging show osteopenia, osteoclastic subperiosteal bone
    resorption, marrow fibrosis, increased osteoid, and other features of a
    metabolic bone disorder.
  evidence:
  - reference: PMID:12705498
    reference_title: The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "transiliac bone biopsy demonstrated both trabecular osteopenia and marked subperiosteal bone resorption."
    explanation: Bone biopsy supports osteodystrophy and osteopenic/resorptive pathology.
  - reference: PMID:21466370
    reference_title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bone histopathology has been characterized by vigorous osteoclastic subperiosteal bone resorption, endosteal modeling, slight marrow fibrosis, and an increase in the amount of osteoid present."
    explanation: Autopsy review supports characteristic bone histopathologic changes.
diagnosis:
- name: Lysosomal hydrolase and phosphotransferase enzyme testing
  description: >
    Diagnostic enzyme testing evaluates the characteristic hydrolase
    distribution pattern and confirms deficient GlcNAc-1-phosphotransferase
    activity.
  results: Elevated plasma hydrolases with deficient cellular enzyme activity and low phosphotransferase activity support ML III alpha/beta.
  evidence:
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Significant deficiency (1%-10% of normal) of the activity of the enzyme UDP-N-acetylglucosamine: lysosomal hydrolase N-acetylglucosamine-1-phosphotransferase (GNPTA), encoded by GNPTAB, confirms the diagnosis."
    explanation: GeneReviews supports phosphotransferase activity testing as confirmatory.
  - reference: PMID:20367762
    reference_title: The natural history and osteodystrophy of mucolipidosis types II and III.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis of all patients, with one exception, was confirmed enzymatically"
    explanation: Natural-history cohort supports enzymatic confirmation.
- name: GNPTAB molecular genetic testing
  description: >
    Sequencing or other molecular testing confirms biallelic pathogenic GNPTAB
    variants and supports familial carrier testing and reproductive risk
    assessment.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  results: Biallelic pathogenic GNPTAB variants confirm ML III alpha/beta.
  evidence:
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bidirectional sequencing of the entire GNPTAB coding region detects two pathogenic variants in more than 95% of individuals with ML III alpha/beta."
    explanation: GeneReviews supports GNPTAB sequencing as a high-yield confirmatory test.
  - reference: PMID:30208878
    reference_title: "GNPTAB c.2404C > T nonsense mutation in a patient with mucolipidosis III alpha/beta: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "genetic study, which confirmed the parental origin of both mutations"
    explanation: Case report supports combined enzyme and genetic testing in ML III alpha/beta diagnosis.
- name: Skeletal radiography
  description: >
    Radiographs help identify dysostosis multiplex, osteodystrophy, spinal
    deformity, hip dysplasia, osteolysis, and other skeletal complications.
  evidence:
  - reference: PMID:20367762
    reference_title: The natural history and osteodystrophy of mucolipidosis types II and III.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In all patients surviving the first year of life, skeletal radiographs showed a mixture of osteodystrophic bone changes and atypical changes of dysostosis multiplex."
    explanation: Natural-history cohort supports skeletal radiography for the characteristic bone phenotype.
  - reference: PMID:10472261
    reference_title: Orthopaedic management in four cases of mucolipidosis type III.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Radiographs showed spinal deformities and hip dysplasia"
    explanation: Orthopedic case series supports radiography for spinal and hip skeletal complications.
treatments:
- name: Supportive multisystem surveillance and care
  description: >
    Supportive management includes low-impact therapy, monitoring for skeletal,
    bone-pain, cardiac, respiratory, and airway/anesthesia complications, and
    follow-up frequency tailored to disease course.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Bone pain
    term:
      id: HP:0002653
      label: Bone pain
  - preferred_term: Loss of ambulation
    term:
      id: HP:0002505
      label: Loss of ambulation
  - preferred_term: Recurrent otitis media
    term:
      id: HP:0000403
      label: Recurrent otitis media
  - preferred_term: Recurrent upper respiratory tract infections
    term:
      id: HP:0002788
      label: Recurrent upper respiratory tract infections
  - preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
  evidence:
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "annual routine follow-up visits after age six years unless bone pain, deteriorating ambulation, and/or cardiac and respiratory monitoring need more frequent attention."
    explanation: GeneReviews supports longitudinal supportive surveillance for bone, ambulation, cardiac, and respiratory complications.
- name: Physical therapy for joint stiffness and contractures
  description: >
    Low-impact physical therapy and physiotherapy are used to maintain mobility
    and manage joint stiffness, hip or knee contractures, and functional
    limitations.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
  target_phenotypes:
  - preferred_term: Joint stiffness
    term:
      id: HP:0001387
      label: Joint stiffness
  - preferred_term: Flexion contracture
    term:
      id: HP:0001371
      label: Flexion contracture
  evidence:
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Low-impact physical therapy is usually well tolerated."
    explanation: GeneReviews supports low-impact physical therapy for manifestations.
  - reference: PMID:10472261
    reference_title: Orthopaedic management in four cases of mucolipidosis type III.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "joint stiffness and hip and knee contractures were managed by physiotherapy."
    explanation: Orthopedic case series supports physiotherapy for joint stiffness and contractures.
- name: Orthopedic and carpal tunnel surgery
  description: >
    Surgical management may include carpal tunnel release and orthopedic
    procedures such as hip replacement for severe skeletal disease, with
    anesthesia planning in tertiary centers because airway risk can be elevated.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  target_phenotypes:
  - preferred_term: Constrictive median neuropathy
    term:
      id: HP:0012185
      label: Constrictive median neuropathy
  - preferred_term: Bone pain
    term:
      id: HP:0002653
      label: Bone pain
  evidence:
  - reference: PMID:10472261
    reference_title: Orthopaedic management in four cases of mucolipidosis type III.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Carpal tunnel syndrome was treated surgically"
    explanation: Orthopedic case series supports carpal tunnel surgery.
  - reference: PMID:29704188
    reference_title: Mucolipidosis type III, a series of adult patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients underwent multiple orthopaedic surgical interventions as early as the second or third decades of life, of which total hip replacement (THR) was the most common procedure (61% of patients)."
    explanation: Adult cohort supports orthopedic surgical intervention, especially total hip replacement.
- name: Intravenous pamidronate for bone pain
  description: >
    Intravenous pamidronate has been reported as an adjunctive bisphosphonate
    treatment for ML III osteodystrophy and bone pain, improving pain and
    mobility in two siblings despite incomplete biochemical and histologic
    correction.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: pamidronate
      term:
        id: CHEBI:7903
        label: pamidronate
  target_phenotypes:
  - preferred_term: Bone pain
    term:
      id: HP:0002653
      label: Bone pain
  - preferred_term: Generalized osteoporosis
    term:
      id: HP:0040160
      label: Generalized osteoporosis
  target_mechanisms:
  - target: Skeletal and joint degeneration
    treatment_effect: MODULATES
    description: Pamidronate targets high-turnover bone disease and bone pain downstream of ML III osteodystrophy.
    evidence:
    - reference: PMID:12705498
      reference_title: The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Biochemical indices of bone turnover were increased"
      explanation: The treatment study identifies elevated bone turnover as the therapeutic target.
  evidence:
  - reference: PMID:12705498
    reference_title: The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intravenous pamidronate treatment given monthly for a year was well tolerated and produced dramatic clinical effects, with reduction in bone pain and improvements in mobility"
    explanation: Study reports symptomatic improvement after intravenous pamidronate.
  - reference: PMID:12705498
    reference_title: The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bisphosphonate therapy may have an important role in the management of bone pain in ML III"
    explanation: Study conclusion supports bisphosphonates as bone-pain management in ML III.
- name: Genetic counseling
  description: >
    Genetic counseling informs recurrence risk, carrier testing, and prenatal or
    family-based testing when familial GNPTAB pathogenic variants are known.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:20301730
    reference_title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants in the family are known."
    explanation: GeneReviews supports genetic counseling for carrier and prenatal risk assessment.
notes: >
  The PubMed cache for PMID:20301730 is an archival retired GeneReviews chapter;
  it is used only for exact diagnostic, inheritance, management, and genetic
  counseling snippets that are consistent with more recent cohort evidence.
  The primary disease definition, inheritance, GNPTAB assertion, mappings, and
  phenotype frequencies are anchored to ORPHA:423461.
classifications:
  harrisons_chapter:
  - classification_value: hereditary disease
references:
- reference: ORPHA:423461
  title: Mucolipidosis type III alpha/beta
- reference: PMID:20301730
  title: Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
  tags:
  - GeneReviews
- reference: DOI:10.1136/jmg.2009.067736
  title: "Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands"
- reference: PMID:19197337
  title: "Mucolipidosis II and III alpha/beta: mutation analysis of 40 Japanese patients showed genotype-phenotype correlation."
- reference: PMID:20367762
  title: The natural history and osteodystrophy of mucolipidosis types II and III.
- reference: PMID:21466370
  title: "Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy."
- reference: PMID:30208878
  title: "GNPTAB c.2404C > T nonsense mutation in a patient with mucolipidosis III alpha/beta: a case report."
- reference: PMID:12705498
  title: The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.
- reference: PMID:29704188
  title: Mucolipidosis type III, a series of adult patients.
- reference: PMID:32818557
  title: A Rare Manifestation of Right Ventricular Dysfunction in an Adult Patient With Mucolipidosis Type III alpha/beta.
- reference: PMID:10472261
  title: Orthopaedic management in four cases of mucolipidosis type III.

📚

References & Deep Research

References

11

ORPHA:423461

Mucolipidosis type III alpha/beta

No top-level findings curated for this source.

PMID:20301730

Mucolipidosis III Alpha/Beta - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.

No top-level findings curated for this source.

DOI:10.1136/jmg.2009.067736

Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands

No top-level findings curated for this source.

PMID:19197337

Mucolipidosis II and III alpha/beta: mutation analysis of 40 Japanese patients showed genotype-phenotype correlation.

No top-level findings curated for this source.

PMID:20367762

The natural history and osteodystrophy of mucolipidosis types II and III.

No top-level findings curated for this source.

PMID:21466370

Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy.

No top-level findings curated for this source.

PMID:30208878

GNPTAB c.2404C > T nonsense mutation in a patient with mucolipidosis III alpha/beta: a case report.

No top-level findings curated for this source.

PMID:12705498

The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.

No top-level findings curated for this source.

PMID:29704188

Mucolipidosis type III, a series of adult patients.

No top-level findings curated for this source.

PMID:32818557

A Rare Manifestation of Right Ventricular Dysfunction in an Adult Patient With Mucolipidosis Type III alpha/beta.

No top-level findings curated for this source.

PMID:10472261

Orthopaedic management in four cases of mucolipidosis type III.

No top-level findings curated for this source.

Deep Research

1

Mucolipidosis Type III Alpha/Beta Deep Research Fallback ▸

Mucolipidosis Type III Alpha/Beta Deep Research Fallback

Provider Attempts

2026-05-08T04:39Z: just research-disorder openai Mucolipidosis_Type_III_Alpha_Beta was attempted before the YAML existed and failed immediately because the disorder file was not found.
2026-05-08T04:53Z: just research-disorder openai Mucolipidosis_Type_III_Alpha_Beta started after YAML creation but produced no output during the bounded wait. The provider process did not accept stdin interrupt through the session, so the process tree was terminated with SIGTERM.

No provider-generated deep-research narrative was available within the bounded runtime. Curation proceeded from regenerated Orphanet structured evidence and fetched PubMed/DOI caches, without creating or hand-editing any references_cache/*.md files.

Evidence Scope Used

ORPHA:423461 for the exact disease record, MONDO and OMIM mappings, autosomal recessive inheritance, GNPTAB disease-gene association, epidemiology, and all structured HPO phenotype frequency rows.
PMID:20301730 for diagnostic enzyme testing, GNPTAB sequencing, management, surveillance, inheritance, and genetic counseling snippets, with the YAML noting that the cached GeneReviews chapter is archival/retired.
DOI:10.1136/jmg.2009.067736 and PMID:19197337 for GNPTAB causation, phosphotransferase deficiency, and residual-activity genotype-phenotype framing.
PMID:20367762 for natural history, lysosomal hydrolase disparity, skeletal radiographic changes, dysostosis multiplex, and osteodystrophy.
PMID:21466370 for autopsy and histopathology evidence covering lysosomal granular storage in multiple organs, cartilage, bone, and cardiac valve pathology.
PMID:29704188, PMID:10472261, PMID:12705498, and PMID:32818557 for adult skeletal disease, orthopedic intervention, physical therapy, pamidronate, and cardiac involvement.
PMID:30208878 for a GNPTAB-confirmed ML III alpha/beta case report and diagnostic use of enzyme and genetic testing.

Curation Conclusions

The curated model is biallelic GNPTAB pathogenic variation causing reduced UDP-N-acetylglucosamine-1-phosphotransferase activity. Loss of the mannose-6-phosphate recognition marker prevents efficient lysosomal targeting of hydrolases, leading to extracellular hydrolase leakage, intracellular lysosomal storage, and a multisystem but attenuated ML III phenotype. The most evidence-backed clinical axis is skeletal and joint degeneration, with secondary cardiac-valve, biochemical, ENT/hearing, growth, and mild cognitive manifestations. Current management in the cached literature is supportive and complication-directed, including physical therapy, orthopedic/carpal tunnel surgery, pamidronate for bone pain in limited human evidence, surveillance, and genetic counseling.

Mucolipidosis Type III Alpha/Beta

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Definitions

Inheritance

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

Mucolipidosis Type III Alpha/Beta Deep Research Fallback

Provider Attempts

Evidence Scope Used

Curation Conclusions